|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ADAMTSL2 |
Gene summary for ADAMTSL2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ADAMTSL2 | Gene ID | 9719 |
| Gene name | ADAMTS like 2 | |
| Gene Alias | ADAMTSL-2 | |
| Cytomap | 9q34.2 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q86TH1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9719 | ADAMTSL2 | A001-C-119 | Human | Colorectum | FAP | 4.58e-11 | 6.60e-01 | -0.1557 |
| 9719 | ADAMTSL2 | A001-C-108 | Human | Colorectum | FAP | 2.27e-03 | 2.87e-01 | -0.0272 |
| 9719 | ADAMTSL2 | A002-C-021 | Human | Colorectum | FAP | 3.69e-05 | 2.38e-01 | 0.1171 |
| 9719 | ADAMTSL2 | A001-C-014 | Human | Colorectum | FAP | 8.44e-04 | 3.07e-01 | 0.0135 |
| 9719 | ADAMTSL2 | A001-C-203 | Human | Colorectum | FAP | 1.71e-02 | 1.46e-01 | -0.0481 |
| 9719 | ADAMTSL2 | F034 | Human | Colorectum | FAP | 1.24e-02 | 2.91e-01 | -0.0665 |
| 9719 | ADAMTSL2 | F072B | Human | Colorectum | FAP | 1.36e-02 | 1.77e-01 | 0.257 |
| 9719 | ADAMTSL2 | CRC-1-8810 | Human | Colorectum | CRC | 7.56e-03 | 2.78e-01 | 0.6257 |
| 9719 | ADAMTSL2 | CRC-3-11773 | Human | Colorectum | CRC | 8.13e-03 | 1.60e-01 | 0.2564 |
| 9719 | ADAMTSL2 | cirrhotic3 | Human | Liver | Cirrhotic | 8.08e-03 | 1.87e-01 | 0.0215 |
| 9719 | ADAMTSL2 | S014 | Human | Liver | HCC | 2.18e-10 | 4.30e-01 | 0.2254 |
| 9719 | ADAMTSL2 | S015 | Human | Liver | HCC | 5.18e-12 | 7.33e-01 | 0.2375 |
| 9719 | ADAMTSL2 | S016 | Human | Liver | HCC | 6.93e-17 | 5.82e-01 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00715591 | Colorectum | FAP | response to transforming growth factor beta | 63/2622 | 256/18723 | 3.82e-06 | 1.32e-04 | 63 |
| GO:00071782 | Colorectum | FAP | transmembrane receptor protein serine/threonine kinase signaling pathway | 81/2622 | 355/18723 | 4.28e-06 | 1.46e-04 | 81 |
| GO:00715601 | Colorectum | FAP | cellular response to transforming growth factor beta stimulus | 61/2622 | 250/18723 | 7.22e-06 | 2.19e-04 | 61 |
| GO:00071791 | Colorectum | FAP | transforming growth factor beta receptor signaling pathway | 50/2622 | 198/18723 | 1.75e-05 | 4.44e-04 | 50 |
| GO:0017015 | Colorectum | FAP | regulation of transforming growth factor beta receptor signaling pathway | 31/2622 | 128/18723 | 1.35e-03 | 1.24e-02 | 31 |
| GO:1903844 | Colorectum | FAP | regulation of cellular response to transforming growth factor beta stimulus | 31/2622 | 131/18723 | 2.01e-03 | 1.67e-02 | 31 |
| GO:0090092 | Colorectum | FAP | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 52/2622 | 256/18723 | 3.33e-03 | 2.44e-02 | 52 |
| GO:0060428 | Colorectum | FAP | lung epithelium development | 12/2622 | 37/18723 | 3.43e-03 | 2.48e-02 | 12 |
| GO:0030323 | Colorectum | FAP | respiratory tube development | 39/2622 | 181/18723 | 3.60e-03 | 2.58e-02 | 39 |
| GO:0030324 | Colorectum | FAP | lung development | 38/2622 | 177/18723 | 4.28e-03 | 2.93e-02 | 38 |
| GO:00071783 | Colorectum | CRC | transmembrane receptor protein serine/threonine kinase signaling pathway | 66/2078 | 355/18723 | 1.74e-05 | 5.28e-04 | 66 |
| GO:00715592 | Colorectum | CRC | response to transforming growth factor beta | 51/2078 | 256/18723 | 2.33e-05 | 6.65e-04 | 51 |
| GO:00715602 | Colorectum | CRC | cellular response to transforming growth factor beta stimulus | 49/2078 | 250/18723 | 5.17e-05 | 1.19e-03 | 49 |
| GO:00071792 | Colorectum | CRC | transforming growth factor beta receptor signaling pathway | 39/2078 | 198/18723 | 2.58e-04 | 4.19e-03 | 39 |
| GO:00900921 | Colorectum | CRC | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 46/2078 | 256/18723 | 6.66e-04 | 8.77e-03 | 46 |
| GO:00303231 | Colorectum | CRC | respiratory tube development | 34/2078 | 181/18723 | 1.47e-03 | 1.57e-02 | 34 |
| GO:00170151 | Colorectum | CRC | regulation of transforming growth factor beta receptor signaling pathway | 26/2078 | 128/18723 | 1.63e-03 | 1.70e-02 | 26 |
| GO:00604281 | Colorectum | CRC | lung epithelium development | 11/2078 | 37/18723 | 1.69e-03 | 1.75e-02 | 11 |
| GO:00303241 | Colorectum | CRC | lung development | 33/2078 | 177/18723 | 1.94e-03 | 1.96e-02 | 33 |
| GO:19038441 | Colorectum | CRC | regulation of cellular response to transforming growth factor beta stimulus | 26/2078 | 131/18723 | 2.29e-03 | 2.20e-02 | 26 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ADAMTSL2 | SNV | Missense_Mutation | novel | c.2734N>T | p.Pro912Ser | p.P912S | Q86TH1 | protein_coding | deleterious(0) | possibly_damaging(0.743) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
| ADAMTSL2 | SNV | Missense_Mutation | novel | c.418T>C | p.Tyr140His | p.Y140H | Q86TH1 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ADAMTSL2 | SNV | Missense_Mutation | novel | c.1361N>T | p.Ser454Leu | p.S454L | Q86TH1 | protein_coding | tolerated(0.23) | benign(0.005) | TCGA-C8-A12O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ADAMTSL2 | SNV | Missense_Mutation | c.863N>A | p.Arg288Gln | p.R288Q | Q86TH1 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C8-A131-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| ADAMTSL2 | SNV | Missense_Mutation | novel | c.2629G>A | p.Asp877Asn | p.D877N | Q86TH1 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| ADAMTSL2 | deletion | Frame_Shift_Del | novel | c.2372delN | p.Asp791AlafsTer83 | p.D791Afs*83 | Q86TH1 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ADAMTSL2 | SNV | Missense_Mutation | novel | c.1582G>A | p.Glu528Lys | p.E528K | Q86TH1 | protein_coding | tolerated(0.11) | benign(0.411) | TCGA-C5-A1M9-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| ADAMTSL2 | SNV | Missense_Mutation | rs762657949 | c.89N>T | p.Thr30Met | p.T30M | Q86TH1 | protein_coding | tolerated(0.1) | benign(0.092) | TCGA-C5-A7XC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ADAMTSL2 | SNV | Missense_Mutation | novel | c.1702T>A | p.Trp568Arg | p.W568R | Q86TH1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ADAMTSL2 | SNV | Missense_Mutation | novel | c.1760N>T | p.Ala587Val | p.A587V | Q86TH1 | protein_coding | deleterious(0) | benign(0.022) | TCGA-EK-A2RK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |